ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,330.30
-0.28%
S&P ASX All Technology
3,856.20
0.14%
Brent Oil
73.155
-0.39%
US Dollar vs AUD
1.56438
-0.14%
Bitcoin
101,112.46
-0.08%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. I MAB (IMAB)

  7. I MAB (IMAB) News

I MAB

I MAB (IMAB)

NASDAQ
1.04
-0.02
(-1.89%)
Closed 12 December 8:00AM
Delayed by 15 minutes
1.065
0.025
( 2.40% )
Pre Market: 12:16AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

IMAB News

Official News Only

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
14 November 2024
IMAB (-1.89%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
06 November 2024
IMAB (-1.89%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
06 November 2024
IMAB (-1.89%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
24 October 2024
IMAB (-1.89%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
23 September 2024
IMAB (-1.89%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
17 September 2024
IMAB (-1.89%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
31 August 2024
IMAB (-1.89%)

IMAB Discussion

View Posts
glenn1919 glenn1919 2 months ago
IMAB.......................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 months ago
IMAB.................................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 3 months ago
IMAB under $2
👍️0
Monksdream Monksdream 5 months ago
IMAB under $2
👍️0
Monksdream Monksdream 5 months ago
IMAB under $2
👍️0
stock1ace1 stock1ace1 7 months ago
Imab $1.80 golden cross https://schrts.co/CNBigxhc

I-Mab Price Target Maintained With a $6.00/Share by Needham
Mentioned: IMAB

Ratings actions from Benzinga: https://www.benzinga.com/quote/IMAB/analyst-ratings

(END) Dow Jones Newswires

April 12, 2024 06:15 ET (10:15 GMT)
👍️0
Monksdream Monksdream 8 months ago
IMAB 10Q due 4/3
👍️0
Monksdream Monksdream 9 months ago
IMAB under $2=
👍️0
Monksdream Monksdream 9 months ago
IMAB under $2
👍️0
Monksdream Monksdream 10 months ago
IMAB under $2
👍️0
AGORDON AGORDON 10 months ago
IMAB
This is a long-term deal. The China divestiture had to be done to facilitate the future sale of the company. There would be too many Chinese entities to satisfy and hence introduce uncertainty in a future sale. The loss of the Jumpcan deal is a negative because the numbers were spelled out. I will feel much more comfortable about IMAB after they get a Giva or a Uli licensing deal. Combined, based on prior deals for similar drugs would be worth $1B+. It is likely they will have to pay out $30M to the non participants. The $80M from Hangzhou will take years to collect. But, there is one point that has not been addressed. That is the pricing of drugs in China. The Chinese government is notorious for asking for discounts. The pricing of drugs in the USA is better. IMAB has shifted its focus to drugs in a market where they will get much better pricing. The unknown is will IMAB get a deal for Giva, or Uli ?
👍️0
AGORDON AGORDON 12 months ago
2-3 minutes before the close over 500k shares were dumped. Same exercise happened to several Chinese stocks.
👍️0
AGORDON AGORDON 12 months ago
Based on the Astra Zeneca agreement with KYM for their Claudin 18.2 drug, and the Antengene agreement with Calithera for their CD73 inhibitor drug, I estimate that IMAB has potential contracts worth $1.25B+.
👍️0
AGORDON AGORDON 12 months ago
Why doesn't IMAB license Givasgtomig and Ulilidimab? I estimate that the milestone payments would be at least $500M. The share would be at least $5.
👍️0
AGORDON AGORDON 1 year ago
From the 20-F report

On July 16, 2022, I-Mab Hangzhou entered into a definitive financing agreement with a group of domestic investors in China to raise approximately US$46 million (in RMB equivalent). On the same date, we, through our wholly-owned subsidiary, entered into a shareholders agreement with I-Mab Hangzhou and other domestic investors in I-Mab Hangzhou named therein (the “I-Mab Hangzhou Shareholders Agreement”). Upon the occurrence of certain triggering events as specified in the I-Mab Hangzhou Shareholders Agreement, including but not limited to I-Mab Hangzhou’s failure to accomplish certain public offering condition, we may be obligated to repurchase the equity held by other domestic investors in cash or in our stocks in the period beyond 12 months.
👍️0
AGORDON AGORDON 1 year ago
In the most recent reporting period, Decheng Capital purchased 4 million shares of IMAB.
👍️0
AGORDON AGORDON 1 year ago
The stock has bounced off $1.80 two times within a month.
👍️0
AGORDON AGORDON 1 year ago
Not a surprise to see a pull back from the +50% rise last week. A large order came in at the end of yesterday. Nevertheless, it is disappointing to see the slide. It could fall back to $1.28. Mr. Kannan will be at a conference on 11/14. I think the China approvals will send the stock past $3 next year. The company will be sold by the end of 2025.
👍️0
Mt. Blanc Mt. Blanc 1 year ago
IMAB climbing the charts tracking the $3s. Check it out soon.

mb
👍️0
Monksdream Monksdream 1 year ago
IMAB under $2
👍️0

Your Recent History

NASDAQ
IMAB
I MAB
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved